Abstract: Objective To study the clinical efficacy and safety of different western medicine regimens for the treatment of IgA nephropathy. Methods A total of 72 patients with IgA nephropathy admitted to Gaozhou people's hospital from January 2016 to June 2018 were studied. They were divided into cyclophosphamide group, mycophenolate group and control group according to the random number table method, with 24 patients in each group. The control group was treated with glucocorticoid alone, the cyclophosphamide group with glucocorticoid combined with cyclophosphamide, and the mycophenolate group with glucocorticoid combined with mycophenolate. Patients in the three groups were followed up for 6 months to compare the clinical efficacy, biochemical indexes and incidence of adverse reactions before and after treatment. Results The total effective rate of clinical treatment was not obvious in the patients with different Haas types in the cyclophosphamide group, the mycophenolate group and the control group (all P>0.05). After treatment, the levels of 24-hour urine protein, and serum creatinine, urea and uric acid in the cyclophosphamide group and mycophenolate group were lower than the control group (all P<0.05). However, there was no significant difference in the above indexes between cyclophosphamide group and mycophenolate group (all P>0.05).The incidence of adverse reactions in the mycophenolate group was 0.00% (0/24), which was lower than those in the cyclophosphamide group 16.67% (4/24) and the control group 25.00% (6/24) (both P<0.05). Conclusions Glucocorticoid combined cyclophosphamide and glucocorticoid combined mycophenolate for treatment of IgA nephropathy patients achieve comparable clinical effects, but the latter has a lower incidence of adverse reactions and higher safety, and so is worthy of clinical popularization and application.